Back to Journals » OncoTargets and Therapy » Volume 10

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status

Total article views   Abstract views HTML views PDF downloads Totals
3,570 Dovepress* 2,666 609+ 954 3,275
PubMed Central* 0 295 148 295
Totals 2,666 904 1,102 3,570
*Since 18 January 2017
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 2 2

View citations on PubMed Central and Google Scholar